Articles tagged with Protease Inhibitors
Researchers have developed an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma. The experimental targeted protein degrader enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs, while showing limited toxicity.
A new study reveals that combining proteasome inhibitors with Lys05 can effectively kill AML cells by disabling backup survival pathways. This approach has shown promise in preclinical models and could lead to improved treatment options for a wider range of AML patients.
Combining PCSK9 inhibitors with anti-PD-1/PD-L1 treatment may improve antitumor effects. PCSK9 inhibition enhances antigen presentation, promoting T cell recognition and killing of tumor cells.
Scientists at The Wistar Institute have identified a novel series of SARS-CoV-2 Mpro inhibitors that effectively inhibit viral replication in vitro against multiple COVID variants. These compounds also synergize with existing antivirals, offering promise for developing future therapies.
A Stanford University research team has developed a potential new anti-coronavirus drug that binds more tightly and durably than current treatments like Paxlovid. The compound, ML2006a4, performed well in preclinical experiments against SARS-CoV-2 variants that have evolved resistance to Paxlovid.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
A team at Penn State has produced high-resolution images of SARS-CoV-2's protease protein and polyprotein complex. The research reveals a consistent order in which the proteins are cleaved, potentially supporting more efficient antiviral drugs.
Researchers at the Center for One Health Research have found that antiviral drugs can make antifungals work again by blocking efflux pumps in Candida auris. This approach may be a key treatment strategy against the deadly fungal pathogen, which has a 60% mortality rate.
Researchers found that metformin + leucine (MET+LEU) treatment prevents myotube atrophy by reversing cellular senescence and improving proteostasis. The study used C2C12 myoblasts, aged mouse single myofibers, and human primary myotubes to demonstrate MET+LEU's skeletal muscle cell-autonomous properties.
A study published in Science Advances reveals that viral SARS-CoV-2 variants are developing resistance to protease inhibitors, including Paxlovid. Researchers warn that this could undermine the effectiveness of antiviral treatments and highlight the need for next-generation compounds with different resistance profiles.
Wild potato varieties have evolved multiple resistance factors to combat pathogens like Pectobacterium species. Researchers have identified protease inhibitors that prevent bacterial malignance by interrupting their communication system and degrading plant cell walls.
Researchers at CNIO have identified epigenetic changes, specifically DNA methylation, as a key mechanism behind resistance to proteasome inhibitor drugs in multiple myeloma. This finding suggests that methylation levels in the PSMD5 gene can predict treatment response and potentially reverse resistance.
Researchers found that overexpressing matriptase reduced myeloma cell proliferation and inhibited migration. Matriptase also blocked Src kinase activation, supporting its potential as a tumor suppressor in multiple myeloma. The study provides new insights into the role of matriptase in hematological malignancies.
Researchers at Kyoto University have developed a cancer therapy model that utilizes a protein degrading system to transiently degrade and reduce the PD-1 protein, which blocks immune function. This approach has shown high therapeutic efficacy in inhibiting cancer cell growth in mice.
A new study from Karolinska Institutet has identified a key mechanism behind treatment resistance in a deadly form of kidney cancer. By increasing mitochondrial content in cancer cells, researchers found that these cells became susceptible to the cancer drug sorafenib. This breakthrough offers hope for more targeted cancer treatments.
Researchers elucidated the protease-inhibitory mechanism of A2ML1 using cryo-EM structures, shedding light on its role in severe autoimmune blistering diseases. The study improves understanding of related proteins and their function.
Researchers from Goethe University and University of Kent found aprotinin effective against SARS-CoV-2 variants, including Delta and Omicron, by preventing virus entry into host cells. A recent phase III clinical study demonstrated the treatment reduced hospital stays by five days.
A French study suggests that long-term use of protease inhibitors may lower the risk of COVID-19 infection by 70%. The study found that patients taking PIs had a lower incidence of COVID-19 compared to those not on PIs, despite having similar risk factors.
A CHOP-led study found bortezomib significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma. The trial also showed that intensifying the chemotherapy regimen allowed for elimination of radiation in nearly all patients, resulting in excellent outcomes.
Scientists discovered two new targets, EPPIN domains, to block sperm motility, a complex process that allows sperm to reach the egg. The study demonstrates the feasibility of using mice as models for in vivo trials, simplifying preclinical studies and paving the way for novel male contraceptives.
Researchers identified a novel therapeutic target for multiple myeloma by discovering the Sec61 translocon's vulnerability to inhibition. This targets the translocon prevents multiple myeloma cells from producing proteins through the secretory pathway, leading to their death.
A study published in Nature Communications reveals the mechanisms of SARS-CoV-2 proteolysis and identifies key cellular substrates with therapeutic potential. The research provides a powerful resource for developing targeted strategies to inhibit the virus, which has caused over 227 million infections and 4.6 million deaths worldwide.
The study reveals that FBS2 protein is responsible for the lethality in NGLY1-knockout mice, causing cell growth suppression and accumulation of ubiquitinated glycoproteins. The absence of NGLY1 leads to proteasome inhibition, resulting in cell death.
Researchers found that animal models infected with SARS-CoV-2 treated with a deuterated protease inhibitor had significantly increased survival and decreased lung viral load. The results suggest that postinfection treatment with inhibitors of proteases essential for viral replication may be an effective treatment against SARS-CoV-2.
A research team has discovered two families of active substances that can block the replication of SARS-CoV-2 by targeting its main protease enzyme. The drug candidates show promise for therapeutic development, but extensive clinical trials are still required.
A Danish research team has discovered a new control mechanism in the innate immune system, involving the ITIH4 protein. The study found that ITIH4 inhibits proteases via an unknown mechanism, preventing damage to healthy cells.
Researchers found that green tea and muscadine grape extracts can inhibit the Mpro enzyme in SARS-CoV-2, while dark chocolate and cacao powder showed reduced activity. The study suggests that these plant compounds could be used to develop new treatments for COVID-19.
Researchers at Goethe University demonstrated that the protease inhibitor aprotinin can inhibit SARS-CoV2 replication by preventing viral entry into host cells. Aprotinin also compensates for reduced endogenous protease inhibitors in virus-infected cells.
Researchers at the Department of Energy's Oak Ridge National Laboratory have discovered that several hepatitis C drugs can effectively bind and inhibit the SARS-CoV-2 main protease. The study provides promising results for potential repurposing candidates to treat COVID-19, paving the way for further research and clinical trials.
Researchers have identified a potential treatment for COVID-19 using the approved protease inhibitor aprotinin, which inhibits SARS-CoV-2 entry into host cells. The study found that aprotinin aerosols may be effective in preventing severe COVID-19 disease when applied early after diagnosis.
A new study published in Science Translational Medicine reveals that small molecule protease inhibitors can effectively block coronavirus replication and improve survival in MERS-CoV-infected mice. The findings suggest that these compounds could be investigated further as a potential therapeutic for human coronavirus infection.
Researchers identified two P. falciparum-selective proteasome inhibitors with potent antimalarial activity against drug-resistant parasites. The inhibitors exhibited low propensity for generating resistance and synergized with multiple antimalarial agents.
Researchers have developed a small molecule that effectively treats visceral leishmaniasis in a mouse model, with favorable pharmacokinetic properties and no safety concerns. The compound targets the proteasome, a cellular recycling machine, by binding to a previously undiscovered site.
A $2 million phase 2 grant will be used to further develop a compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma. The goal is to create a one-two punch when administered with proteasome inhibitors, making it an effective treatment option for patients.
Patients taking ritonavir-boosted protease inhibitors may experience worsening heart failure and cardiovascular death compared to those on non-protease-inhibitor regimens. The study found a doubled risk of hospital readmission within 30 days and increased cardiovascular death within two years.
Researchers reveal curcumin binds to and inhibits DYRK2, impairing cell proliferation and reducing cancer burden. Curcumin's effectiveness may be limited due to its rapid expulsion from the body.
Researchers from the University of Pennsylvania have identified a key player in causing neuronal damage linked to HIV treatment: the enzyme BACE1. Inhibiting this enzyme may offer a new approach to minimizing damage to neurons in patients on antiretroviral therapies.
Scientists at TUM have determined the molecular mechanisms of inhibitors that can selectively thwart the human immunoproteasome. This could lead to the development of new drugs for autoimmune diseases like rheumatoid arthritis and type 1 diabetes.
MGH researchers discovered the role of DDI-1 and PNG-1 in sensing proteasome stress, with potential applications in cancer treatment and Alzheimer's disease. The findings suggest boosting proteasome activity could help treat conditions characterized by abnormal protein deposits.
A team of scientists has determined the 3D structure of the human proteasome in unprecedented detail, revealing its exact mechanism and a crucial role for a previously unknown chemical reaction. This knowledge will pave the way to develop more effective cancer therapies by optimizing inhibitor design and efficacy.
Researchers discovered TJP1's role in identifying patients most likely to benefit from proteasome inhibitors, with low TJP1 levels associated with resistance. The study provides a rationale for using TJP1 as a biomarker for personalized treatment approaches.
A new experimental treatment regimen combining a drug delivery system and URMC-099 has been shown to effectively combat HIV, reducing the need for daily medication. The nanoformulated protease inhibitor and URMC-099 prolonged therapeutic effects by increasing drug concentration in immune cells.
Researchers at Helmholtz Munich have discovered that increased protein turnover by the 26S proteasome is responsible for the activation of myofibroblasts, leading to pulmonary fibrosis. Inhibiting the 26S proteasome can prevent differentiation of primary human lung fibroblasts into myofibroblasts.
Researchers from Mainz and Würzburg have developed new active substances for treating the dengue virus, showing a high effectiveness rate even at low concentrations. The new inhibitors target only dengue viruses without affecting similar Hepatitis C viruses.
Researchers discovered a new mechanism to inhibit proteasomes, a target for cancer therapy, paving the way for more effective and less toxic chemotherapy drugs. A series of molecules based on this mechanism have been developed, and their potential is being tested.
A study published in Hepatology found that SLPI protein plays a critical role in excessive anti-inflammatory responses in acute liver failure, making patients susceptible to sepsis and infection. Inhibiting SLPI protein may help restore immune function and prevent infection in these patients.
A new combination pill of sofosbuvir and ledipasvir has been shown to be highly effective in treating genotype 1 hepatitis C, even in patients with cirrhosis or previous treatment failure. The study found a sustained virological response rate of nearly 97%, offering new hope for patients with currently untreatable virus.
Researchers identified that protease inhibitors prevent virus entry and affect reverse transcription and post-transcription stages of HIV-1 life cycle. Viral envelope protein mutations were associated with resistance to protease inhibitor treatment.
Researchers have identified a link between the tight junction protein TRIC and cochlear hair cell preservation, as well as a potential mechanism for combatting drug-resistant cancers. Additionally, studies have found that donor tissue can lead to cancer formation in transplant recipients, highlighting the importance of careful screening.
Researchers identified a specific pattern of DNA modifications dependent on HPV presence that correlates with improved survival in patients with OPSCC. A new combination therapy for PEL was found to reactivate virus-induced cell lysis and induce cancer cell death, increasing mouse lifespan.
Recent studies demonstrate encouraging data for direct-acting antiviral agents in a wide range of HCV patient populations. The trials showed high SVR12 rates and low adverse events, with some regimens achieving up to 90% success rate, offering new treatment options for patients with genotype 1, 4, 5, or 6.
A Kansas State University-led team is researching an antiviral drug for market use to prevent and treat norovirus infection. The team has identified protease inhibitors with potential for preventing and treating norovirus, a contagious stomach illness infecting 1 in 15 Americans annually.
A combination of anti-HIV drugs reduces malaria incidence among HIV-positive children by 40% compared to NNRTI treatment. High blood levels of anti-malarial drugs in children receiving protease inhibitors may explain their effectiveness.
Scientists have identified a new class of drugs that target the proteasome in a unique way, leading to potential breakthroughs in cancer medication. The newly discovered hydroxyurea structures work more specifically than existing proteasome inhibitors, reducing severe adverse side effects.
A study found that premature infants treated with lopinavir-ritonavir were more likely to experience life-threatening adrenal insufficiency compared to standard zidovudine treatment. Asymptomatic cases were reported, but long-term effects are unclear.
Researchers at TUM have developed a new mechanism for reversible proteasome inhibition, which could lead to improved treatments for cancer and immune reactions. By targeting the immuno-proteasome specifically, they aim to minimize damage caused by side effects.
Researchers at Avila Therapeutics have developed the first-ever covalent irreversible inhibitors of a viral protease, achieving high selectivity and potency. The newly designed compounds irreversibly bind to molecular domains specific to proteases, offering a promising therapeutic approach for hepatitis C infection.
UCSF researchers have successfully restored the missing protein calpain degrades LIS1 protein to near-normal levels in mice with the mouse-model of this defect. The team gave daily injections of a calpain inhibitor to pregnant mice whose fetuses had the mouse-model, resulting in more normal brains and no sign of mental retardation.
University of Illinois researchers found that thiazole antibiotics stabilize other cancer-causing proteins and inhibit the proteasome, a molecular complex degrading old proteins. This inhibition may lead to effective anti-cancer treatment through combination therapy with well-known proteasome inhibitors.